Join
Live feed
·
PRReleasevia Quantisnow
Bristol-Myers Squibb Company logo

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

ByQuantisnow·Wall Street's wire, on your screen.
BMY· Bristol-Myers Squibb Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMY (Bristol-Myers Squibb Company) and more on Quantisnow.